Squarepoint Ops LLC Sells 121,729 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Squarepoint Ops LLC decreased its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 17.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 590,510 shares of the company's stock after selling 121,729 shares during the quarter. Squarepoint Ops LLC owned about 0.49% of 10x Genomics worth $8,480,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of TXG. Atria Wealth Solutions Inc. raised its stake in 10x Genomics by 9.6% during the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after buying an additional 943 shares during the period. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Signaturefd LLC grew its position in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares during the period. Finally, KBC Group NV increased its stake in 10x Genomics by 57.3% during the 4th quarter. KBC Group NV now owns 5,072 shares of the company's stock valued at $73,000 after purchasing an additional 1,847 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Leerink Partnrs lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. The Goldman Sachs Group dropped their price target on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday. JPMorgan Chase & Co. lowered their price objective on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Finally, Barclays cut their target price on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $15.81.

10x Genomics Trading Up 5.1%

Shares of NASDAQ:TXG traded up $0.42 during midday trading on Tuesday, reaching $8.59. The company had a trading volume of 2,653,754 shares, compared to its average volume of 2,390,875. The stock has a market cap of $1.06 billion, a P/E ratio of -5.65 and a beta of 1.94. The company's 50 day moving average price is $8.54 and its 200 day moving average price is $11.97. 10x Genomics, Inc. has a 52-week low of $6.78 and a 52-week high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business had revenue of $154.88 million for the quarter, compared to analyst estimates of $131.91 million. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. The company's revenue for the quarter was down 2.3% on a year-over-year basis. Research analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.